-
公开(公告)号：US09586978B2
公开(公告)日：2017-03-07
申请号：US14558318
申请日：2014-12-02
Applicant: AbbVie Inc.
Inventor： Mary E. Bellizzi , David A. Betebenner , Jean C. Califano , William A. Carroll , Daniel D. Caspi , David A. DeGoey , Pamela L. Donner , Charles A. Flentge , Yi Gao , Charles W. Hutchins , Douglas K. Hutchinson , Tammie K. Jinkerson , Warren M. Kati , Ryan G. Keddy , Allan C. Krueger , Wenke Li , Dachun Liu , Clarence J. Maring , Mark A. Matulenko , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , John K. Pratt , John T. Randolph , Todd W. Rockway , Kathy Sarris , Michael D. Tufano , Seble H. Wagaw , Rolf Wagner , Kevin R. Woller
IPC: A61K38/00 , C07K16/00 , C07F7/02 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D491/113
CPC classification number: A61K31/454 , A61K31/4178 , A61K31/4184 , A61K31/422 , A61K31/435 , A61K31/4355 , A61K31/438 , A61K31/4418 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/695 , A61K45/06 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D491/113 , C07F7/02 , Y02P20/582
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
Abstract translation: 描述了有效抑制丙型肝炎病毒（“HCV”）复制的化合物。 本发明还涉及制备这种化合物的方法，包含这些化合物的组合物，以及使用这些化合物治疗HCV感染的方法。
-
公开(公告)号：US20160002213A1
公开(公告)日：2016-01-07
申请号：US14852984
申请日：2015-09-14
Applicant: AbbVie Inc. , Abbott Products GmbH
Inventor： Clarence J. Maring , John K. Pratt , William A. Carroll , Dachun LIU , David A. Betebenner , Douglas K. Hutchinson , Michael D. Tufano , Todd W. Rockway , Uwe Schoen , Axel Pahl , Adreas Witte
IPC: C07D413/04 , C07D471/04 , A61K31/513 , C07D413/14 , C07D405/04 , A61K31/5395 , A61K31/541
CPC classification number: C07F7/1804 , A61K31/4178 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/437 , A61K31/506 , A61K31/513 , A61K31/5377 , A61K31/5395 , A61K31/541 , A61K31/675 , A61K31/695 , A61K45/06 , B65D88/703 , C07D405/04 , C07D405/14 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07F9/65586 , F16K31/363 , Y10T137/86405 , Y10T137/86421
Abstract: This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
-
公开(公告)号：US09095590B2
公开(公告)日：2015-08-04
申请号：US14230965
申请日：2014-03-31
Applicant: AbbVie Inc.
Inventor： Rolf Wagner , Warren M. Kati , Dachun Liu , Yaya Liu , Kenton L. Longenecker , Clarence J. Maring , John K. Pratt , Todd W. Rockway , Kent D. Stewart , Michael D. Tufano
IPC: C07D239/22 , C07D239/54 , A61K31/513 , C07D401/10 , C07D403/10 , C07D409/10 , C07D413/10 , C07D417/10 , A61K31/5377 , C07D405/10 , C07D417/14
CPC classification number: A61K31/513 , A61K31/5377 , C07D239/22 , C07D239/54 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10 , C07D417/10 , C07D417/14
Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
-
公开(公告)号：US20140315792A1
公开(公告)日：2014-10-23
申请号：US14180886
申请日：2014-02-14
Applicant: AbbVie, Inc.
Inventor： Rolf Wagner , John K. Pratt , Dachun Liu , Michael D. Tufano , David A. DeGoey , Warren M. Kati , Charles W. Hutchins , Pamela L. Dooner , John T. Randolph , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , Mark A. Matulenko , Ryan G. Keddy , Tammie K. Jinkerson , Todd W. Rockway , Clarence J. Maring , Douglas K. Hutchinson , Charles A. Flentge , David A. Betebenner , Kathy Sarris , Kevin R. Woller , Seble H. Wagaw , Jean C. Califano , Wenke Li , Daniel D. Caspi , Mary E. Bellizzi , Yi Gao , Allan C. Krueger
IPC: C07K5/06 , C07D417/14 , C07C33/26 , C07D403/14 , C07C205/19
CPC classification number: C07F9/65583 , C07C33/26 , C07C201/06 , C07C205/19 , C07D207/08 , C07D207/09 , C07D207/16 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D471/04 , C07D491/113 , C07K5/06
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
-
公开(公告)号：US20140080886A1
公开(公告)日：2014-03-20
申请号：US14029333
申请日：2013-09-17
Applicant: AbbVie Inc.
Inventor： Tami J. Pilot-Matias , Preethi Krishnan , Warren M. Kati , Christine A. Collins , Neeta C. Mistry , Clarence J. Maring , David A. DeGoey , John K. Pratt , Dachun Liu , Rolf Wagner
IPC: A61K31/4025 , A61K45/06
CPC classification number: A61K31/4025 , A61K31/401 , A61K45/06 , A61K2300/00
Abstract: Pan-genotypic HCV inhibitors are described. This invention also relates to methods of using these inhibitors to treat HCV infection.
-
Patent Agency Ranking
公开(公告)号：US20210236508A1
公开(公告)日：2021-08-05
申请号：US16996090
申请日：2020-08-18
Applicant: AbbVie Inc.
Inventor： Le Wang , John K. Pratt , Keith F. McDaniel , Yujia Dai , Steven D. Fidanze , Lisa Hasvold , James H. Holms , Warren M. Kati , Dachun Liu , Robert A. Mantei , William J. McClellan , George S. Sheppard , Carol K. Wada
IPC: A61K31/541 , C07D487/04 , C07D471/04 , A61K31/437 , A61K31/5025 , A61K31/5377 , A61K45/06
Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
-
公开(公告)号：US20190015402A1
公开(公告)日：2019-01-17
申请号：US16042447
申请日：2018-07-23
Applicant: AbbVie Inc.
Inventor： Mary E. Bellizzi , David A. Betebenner , Jean-Christophe C. Califano , William A. Carroll , Daniel D. Caspi , David A. DeGoey , Pamela L. Donner , Charles A. Flentge , Yi Gao , Charles W. Hutchins , Douglas K. Hutchinson , Tammie K. Jinkerson , Warren M. Kati , Ryan G. Keddy , Allan C. Krueger , Wenke Li , Dachun Liu , Clarence J. Maring , Mark A. Matulenko , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , John K. Pratt , John T. Randolph , Todd W. Rockway , Kathy Sarris , Michael D. Tufano , Seble H. Wagaw , Rolf Wagner , Kevin R. Woller
IPC: A61K31/454 , A61K31/4418 , C07D401/14 , A61K45/06 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/695 , A61K31/435 , A61K31/4184 , A61K31/422 , A61K31/4355 , A61K31/438 , A61K31/4178 , C07F7/02 , C07D491/113 , C07D453/00 , C07D417/14 , C07D413/14 , C07D405/14 , C07D403/14 , A61K31/4439
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
-
公开(公告)号：US10039754B2
公开(公告)日：2018-08-07
申请号：US15431069
申请日：2017-02-13
Applicant: AbbVie Inc.
Inventor： Mary E. Bellizzi , David A. Betebenner , Jean-Christophe C. Califano , William A. Carroll , Daniel D. Caspi , David A. DeGoey , Pamela L. Donner , Charles A. Flentge , Yi Gao , Charles W. Hutchins , Douglas K. Hutchinson , Tammie K. Jinkerson , Warren M. Kati , Ryan G. Keddy , Allan C. Krueger , Wenke Li , Dachun Liu , Clarence J. Maring , Mark A. Matulenko , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , John K. Pratt , John T. Randolph , Todd W. Rockway , Kathy Sarris , Michael D. Tufano , Seble H. Wagaw , Rolf Wagner , Kevin R. Woller
IPC: A61K38/00 , A61K31/454 , A61K45/06 , A61K31/4184 , A61K31/4439 , A61K31/422 , A61K31/438 , A61K31/4545 , A61K31/695 , A61K31/496 , A61K31/506 , A61K31/4418 , A61K31/5377 , A61K31/4355 , A61K31/4178
CPC classification number: A61K31/454 , A61K31/4178 , A61K31/4184 , A61K31/422 , A61K31/435 , A61K31/4355 , A61K31/438 , A61K31/4418 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/695 , A61K45/06 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D491/113 , C07F7/02 , Y02P20/582
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
-
公开(公告)号：US09637478B2
公开(公告)日：2017-05-02
申请号：US15141556
申请日：2016-04-28
Applicant: AbbVie Inc.
Inventor： David A. Betebenner , John K. Pratt , David A. DeGoey , Pamela L. Donner , Charles A. Flentge , Douglas K. Hutchinson , Warren M. Kati , Allan C. Krueger , Kenton L. Longenecker , Clarence J. Maring , John T. Randolph , Todd W. Rockway , Michael D. Tufano , Rolf Wagner , Dachun Liu
IPC: C07D409/10 , C07D239/54 , A61K31/513 , C07D213/64 , A61K31/4418 , C07C311/08 , A61K31/18 , C07D233/72 , A61K31/4166 , A61K31/27 , C07D263/24 , A61K31/421 , C07D239/10 , C07D207/27 , A61K31/402 , C07D405/10 , C07D403/10 , A61K45/06 , A61K31/425 , C07D275/02
CPC classification number: C07D409/10 , A61K31/18 , A61K31/27 , A61K31/402 , A61K31/4166 , A61K31/421 , A61K31/425 , A61K31/4418 , A61K31/503 , A61K31/513 , A61K45/06 , C07C311/08 , C07D207/27 , C07D213/64 , C07D233/32 , C07D233/72 , C07D239/10 , C07D239/54 , C07D263/22 , C07D263/24 , C07D275/02 , C07D403/10 , C07D405/10 , Y02P20/55
Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
-
公开(公告)号：US09567355B2
公开(公告)日：2017-02-14
申请号：US15240753
申请日：2016-08-18
Applicant: AbbVie Inc. , Abbott Products GmbH
Inventor： Clarence J. Maring , John K. Pratt , William A. Carroll , Dachun Liu , David A. Betebenner , Douglas K. Hutchinson , Michael D. Tufano , Todd W. Rockway , Uwe Schoen , Axel Pahl , Andreas Witte
IPC: C07D413/04 , C07D413/14 , A61K31/5395 , A61K31/541 , A61K31/513 , C07D471/04 , C07D405/04 , C07F7/18 , A61K31/4178 , C07D417/14 , A61K31/427 , A61K31/422 , A61K31/437 , A61K31/506 , A61K31/695 , A61K31/5377
CPC classification number: C07F7/1804 , A61K31/4178 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/437 , A61K31/506 , A61K31/513 , A61K31/5377 , A61K31/5395 , A61K31/541 , A61K31/675 , A61K31/695 , A61K45/06 , B65D88/703 , C07D405/04 , C07D405/14 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07F9/65586 , F16K31/363 , Y10T137/86405 , Y10T137/86421
Abstract: This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
Abstract translation: 本公开涉及：（a）其特别是抑制HCV的化合物及其盐; （b）可用于制备这些化合物和盐的中间体; （c）包含这些化合物和盐的组合物; （d）制备这种中间体，化合物，盐和组合物的方法; （e）使用这些化合物，盐和组合物的方法; 和（f）包含这些化合物，盐和组合物的试剂盒。
-
-
-
-
-
-
-
-
-
Search Results
36
records
(took 0.054 seconds)
